{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T22:48:44Z","timestamp":1769640524368,"version":"3.49.0"},"reference-count":76,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","jccjournal.org","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Critical Care"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1016\/j.jcrc.2017.03.008","type":"journal-article","created":{"date-parts":[[2017,3,15]],"date-time":"2017-03-15T18:19:34Z","timestamp":1489601974000},"page":"41-45","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["The role of vasopressin and the vasopressin type V1a receptor agonist selepressin in septic shock"],"prefix":"10.1016","volume":"40","author":[{"given":"Antonio F.","family":"Saad","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc O.","family":"Maybauer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.jcrc.2017.03.008_bb0005","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1097\/00003246-200107000-00002","article-title":"Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care","volume":"29","author":"Angus","year":"2001","journal-title":"Crit Care Med"},{"issue":"2","key":"10.1016\/j.jcrc.2017.03.008_bb0010","doi-asserted-by":"crossref","first-page":"207","DOI":"10.2174\/187153006777442332","article-title":"Epidemiology of severe sepsis around the world","volume":"6","author":"Angus","year":"2006","journal-title":"Endocr Metab Immune Disord Drug Targets"},{"issue":"5","key":"10.1016\/j.jcrc.2017.03.008_bb0015","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1378\/chest.11-0352","article-title":"Nationwide trends of severe sepsis in the 21st century (2000\u20132007)","volume":"140","author":"Kumar","year":"2011","journal-title":"Chest"},{"issue":"19","key":"10.1016\/j.jcrc.2017.03.008_bb0020","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1056\/NEJMoa010307","article-title":"Early goal-directed therapy in the treatment of severe sepsis and septic shock","volume":"345","author":"Rivers","year":"2001","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.jcrc.2017.03.008_bb0025","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1007\/s11908-007-0059-3","article-title":"Long-term outcomes from sepsis","volume":"9","author":"Yende","year":"2007","journal-title":"Curr Infect Dis Rep"},{"issue":"6","key":"10.1016\/j.jcrc.2017.03.008_bb0030","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1378\/chest.101.6.1644","article-title":"Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP\/SCCM Consensus Conference Committee. American College of Chest Physicians\/Society of Critical Care Medicine","volume":"101","author":"Bone","year":"1992","journal-title":"Chest"},{"key":"10.1016\/j.jcrc.2017.03.008_bb0035","first-page":"2017","article-title":"Surviving sepsis campaign: International guidelines for management of sepsis and septic shock","author":"Rhodes","year":"2016","journal-title":"Crit Care Med"},{"issue":"9","key":"10.1016\/j.jcrc.2017.03.008_bb0040","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1056\/NEJMoa067373","article-title":"Vasopressin versus norepinephrine infusion in patients with septic shock","volume":"358","author":"Russell","year":"2008","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.jcrc.2017.03.008_bb0045","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1007\/s00134-010-1942-1","article-title":"Best vasopressor for advanced vasodilatory shock: should vasopressin be part of the mix?","volume":"36","author":"Maybauer","year":"2010","journal-title":"Intensive Care Med"},{"issue":"5","key":"10.1016\/j.jcrc.2017.03.008_bb0050","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s00011-011-0314-9","article-title":"Vasopressin analogues and V1a receptor agonists in septic shock","volume":"60","author":"Maybauer","year":"2011","journal-title":"Inflamm Res"},{"issue":"4","key":"10.1016\/j.jcrc.2017.03.008_bb0055","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.phrs.2009.04.009","article-title":"Contractile response of norepinephrine is modulated by caspase-3 in adult rat ventricular myocytes isolated from septic rat heart","volume":"60","author":"Chopra","year":"2009","journal-title":"Pharmacol Res"},{"issue":"1\u20132","key":"10.1016\/j.jcrc.2017.03.008_bb0060","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.jneuroim.2004.08.003","article-title":"Adrenergic modulation of cytokine release in bone marrow progenitor-derived macrophage following polymicrobial sepsis","volume":"158","author":"Muthu","year":"2005","journal-title":"J Neuroimmunol"},{"issue":"1","key":"10.1016\/j.jcrc.2017.03.008_bb0065","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1007\/BF02425154","article-title":"Are the effects of noradrenaline, adrenaline and dopamine infusions on VO2 and metabolism transient?","volume":"21","author":"Ensinger","year":"1995","journal-title":"Intensive Care Med"},{"issue":"9 Suppl","key":"10.1016\/j.jcrc.2017.03.008_bb0070","doi-asserted-by":"crossref","first-page":"S508","DOI":"10.1097\/01.CCM.0000278047.06965.20","article-title":"Glucose metabolism and catecholamines","volume":"35","author":"Barth","year":"2007","journal-title":"Crit Care Med"},{"issue":"9588","key":"10.1016\/j.jcrc.2017.03.008_bb0075","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/S0140-6736(07)61344-0","article-title":"Norepinephrine plus dobutamine versus epinephrine alone for management of septic shock: a randomised trial","volume":"370","author":"Annane","year":"2007","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.jcrc.2017.03.008_bb0080","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1007\/s00134-008-1219-0","article-title":"Santamaria J, investigators CS: a comparison of epinephrine and norepinephrine in critically ill patients","volume":"34","author":"Myburgh","year":"2008","journal-title":"Intensive Care Med"},{"issue":"9","key":"10.1016\/j.jcrc.2017.03.008_bb0085","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1056\/NEJMoa0907118","article-title":"Comparison of dopamine and norepinephrine in the treatment of shock","volume":"362","author":"De Backer","year":"2010","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.jcrc.2017.03.008_bb0090","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1185\/03007995.2015.1085371","article-title":"A new frontier for an old drug? A word of caution for beta-blockers in sepsis!","volume":"31","author":"Maybauer","year":"2015","journal-title":"Curr Med Res Opin"},{"issue":"16","key":"10.1016\/j.jcrc.2017.03.008_bb0095","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1001\/jama.2013.278477","article-title":"Effect of heart rate control with esmolol on hemodynamic and clinical outcomes in patients with septic shock: a randomized clinical trial","volume":"310","author":"Morelli","year":"2013","journal-title":"JAMA"},{"issue":"10","key":"10.1016\/j.jcrc.2017.03.008_bb0100","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1007\/s00134-016-4351-2","article-title":"Heart rate reduction with esmolol is associated with improved arterial elastance in patients with septic shock: a prospective observational study","volume":"42","author":"Morelli","year":"2016","journal-title":"Intensive Care Med"},{"issue":"3","key":"10.1016\/j.jcrc.2017.03.008_bb0105","doi-asserted-by":"crossref","first-page":"R96","DOI":"10.1186\/cc12741","article-title":"Is early ventricular dysfunction or dilatation associated with lower mortality rate in adult severe sepsis and septic shock? A meta-analysis","volume":"17","author":"Huang","year":"2013","journal-title":"Crit Care"},{"issue":"6","key":"10.1016\/j.jcrc.2017.03.008_bb0110","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1007\/s00134-015-3748-7","article-title":"Diastolic dysfunction and mortality in septic patients: a systematic review and meta-analysis","volume":"41","author":"Sanfilippo","year":"2015","journal-title":"Intensive Care Med"},{"issue":"4","key":"10.1016\/j.jcrc.2017.03.008_bb0115","first-page":"F321","article-title":"Osmotic and nonosmotic control of vasopressin release","volume":"236","author":"Schrier","year":"1979","journal-title":"Am J Phys"},{"issue":"2","key":"10.1016\/j.jcrc.2017.03.008_bb0120","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.bpa.2008.03.003","article-title":"Physiology of the vasopressin receptors","volume":"22","author":"Maybauer","year":"2008","journal-title":"Best Pract Res Clin Anaesthesiol"},{"issue":"6","key":"10.1016\/j.jcrc.2017.03.008_bb0125","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/0306-3623(95)00016-T","article-title":"Molecular pharmacology of V1a vasopressin receptors","volume":"26","author":"Howl","year":"1995","journal-title":"Gen Pharmacol"},{"issue":"3","key":"10.1016\/j.jcrc.2017.03.008_bb0130","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1124\/mol.65.3.623","article-title":"Vasopressin stimulates insulin release from islet cells through V1b receptors: a combined pharmacological\/knockout approach","volume":"65","author":"Oshikawa","year":"2004","journal-title":"Mol Pharmacol"},{"issue":"2","key":"10.1016\/j.jcrc.2017.03.008_bb0135","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1677\/joe.0.1560223","article-title":"Structural bases of vasopressin\/oxytocin receptor function","volume":"156","author":"Barberis","year":"1998","journal-title":"J Endocrinol"},{"key":"10.1016\/j.jcrc.2017.03.008_bb0140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-1-4615-4871-3_1","article-title":"Vasopressin receptors. A historical survey","volume":"449","author":"Jard","year":"1998","journal-title":"Adv Exp Med Biol"},{"issue":"2","key":"10.1016\/j.jcrc.2017.03.008_bb0145","doi-asserted-by":"crossref","first-page":"205","DOI":"10.2174\/1381612053382241","article-title":"The central vasopressinergic system: examining the opportunities for psychiatric drug development","volume":"11","author":"Ring","year":"2005","journal-title":"Curr Pharm Des"},{"issue":"5","key":"10.1016\/j.jcrc.2017.03.008_bb0150","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1590\/S0066-782X2003000500002","article-title":"Effect of arginine vasopressin on the canine epicardial coronary artery: experiments on V1-receptor-mediated production of nitric oxide","volume":"80","author":"Evora","year":"2003","journal-title":"Arq Bras Cardiol"},{"issue":"1\u20133","key":"10.1016\/j.jcrc.2017.03.008_bb0155","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/0014-2999(95)00343-J","article-title":"Comparison of responses of canine pulmonary artery and vein to angiotensin II, bradykinin and vasopressin","volume":"282","author":"Sai","year":"1995","journal-title":"Eur J Pharmacol"},{"issue":"3","key":"10.1016\/j.jcrc.2017.03.008_bb0160","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/0196-9781(84)90080-9","article-title":"Evidence that the effects of arginine-8-vasopressin (AVP) on pituitary corticotropin (ACTH) release are mediated by a novel type of receptor","volume":"5","author":"Antoni","year":"1984","journal-title":"Peptides"},{"issue":"4","key":"10.1016\/j.jcrc.2017.03.008_bb0165","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1210\/endo.142.4.8067","article-title":"Immunohistochemical localization of the vasopressin V1b receptor in the rat brain and pituitary gland: anatomical support for its involvement in the central effects of vasopressin","volume":"142","author":"Hernando","year":"2001","journal-title":"Endocrinology"},{"issue":"6","key":"10.1016\/j.jcrc.2017.03.008_bb0170","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1186\/cc2337","article-title":"Science review: Vasopressin and the cardiovascular system part 1--receptor physiology","volume":"7","author":"Holmes","year":"2003","journal-title":"Crit Care"},{"issue":"4","key":"10.1016\/j.jcrc.2017.03.008_bb0175","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/S0955-0674(97)80034-8","article-title":"Regulation of aquaporin-2 water channel trafficking by vasopressin","volume":"9","author":"Knepper","year":"1997","journal-title":"Curr Opin Cell Biol"},{"issue":"2","key":"10.1016\/j.jcrc.2017.03.008_bb0180","first-page":"F526","article-title":"Vasopressin-induced nitric oxide production in rat inner medullary collecting duct is dependent on V2 receptor activation of the phosphoinositide pathway","volume":"293","author":"O'Connor","year":"2007","journal-title":"Am J Phys Renal Phys"},{"issue":"5","key":"10.1016\/j.jcrc.2017.03.008_bb0185","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1161\/01.HYP.32.5.896","article-title":"Arginine vasopressin-mediated stimulation of nitric oxide within the rat renal medulla","volume":"32","author":"Park","year":"1998","journal-title":"Hypertension"},{"issue":"1","key":"10.1016\/j.jcrc.2017.03.008_bb0190","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1172\/JCI9516","article-title":"Vasopressin-induced von Willebrand factor secretion from endothelial cells involves V2 receptors and cAMP","volume":"106","author":"Kaufmann","year":"2000","journal-title":"J Clin Invest"},{"issue":"3","key":"10.1016\/j.jcrc.2017.03.008_bb0195","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1210\/endo.140.3.6546","article-title":"Human vascular endothelial cells express oxytocin receptors","volume":"140","author":"Thibonnier","year":"1999","journal-title":"Endocrinology"},{"issue":"6","key":"10.1016\/j.jcrc.2017.03.008_bb0200","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1590\/S0100-879X2000000600003","article-title":"Oxytocin is a cardiovascular hormone","volume":"33","author":"Gutkowska","year":"2000","journal-title":"Braz J Med Biol Res"},{"issue":"3","key":"10.1016\/j.jcrc.2017.03.008_bb0205","doi-asserted-by":"crossref","first-page":"R98","DOI":"10.1186\/cc7930","article-title":"Low-dose vasopressin infusion results in increased mortality and cardiac dysfunction following ischemia-reperfusion injury in mice","volume":"13","author":"Indrambarya","year":"2009","journal-title":"Crit Care"},{"issue":"4","key":"10.1016\/j.jcrc.2017.03.008_bb0210","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1254\/jjp.66.445","article-title":"Antidiuretic effects of ATP induced by microinjection into the hypothalamic supraoptic nucleus in water-loaded and ethanol-anesthetized rats","volume":"66","author":"Mori","year":"1994","journal-title":"Jpn J Pharmacol"},{"issue":"1","key":"10.1016\/j.jcrc.2017.03.008_bb0215","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s00418-008-0493-9","article-title":"P2X receptors are differentially expressed on vasopressin- and oxytocin-containing neurons in the supraoptic and paraventricular nuclei of rat hypothalamus","volume":"131","author":"Guo","year":"2009","journal-title":"Histochem Cell Biol"},{"issue":"4","key":"10.1016\/j.jcrc.2017.03.008_bb0220","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1046\/j.1538-7836.2003.00190.x","article-title":"Cellular mechanisms of the hemostatic effects of desmopressin (DDAVP)","volume":"1","author":"Kaufmann","year":"2003","journal-title":"J Thromb Haemost"},{"issue":"1 Pt 2","key":"10.1016\/j.jcrc.2017.03.008_bb0225","first-page":"F3","article-title":"Molecular physiology of urinary concentrating mechanism: regulation of aquaporin water channels by vasopressin","volume":"272","author":"Knepper","year":"1997","journal-title":"Am J Phys"},{"key":"10.1016\/j.jcrc.2017.03.008_bb0230","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/7854_2015_390","article-title":"Oxytocin, vasopressin, and the motivational forces that drive social behaviors","volume":"27","author":"Caldwell","year":"2016","journal-title":"Curr Top Behav Neurosci"},{"issue":"5","key":"10.1016\/j.jcrc.2017.03.008_bb0235","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1161\/01.CIR.95.5.1122","article-title":"Vasopressin deficiency contributes to the vasodilation of septic shock","volume":"95","author":"Landry","year":"1997","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.jcrc.2017.03.008_bb0240","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1097\/01.CCM.0000063046.82359.4A","article-title":"Circulating vasopressin levels in septic shock","volume":"31","author":"Sharshar","year":"2003","journal-title":"Crit Care Med"},{"issue":"2","key":"10.1016\/j.jcrc.2017.03.008_bb0245","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1097\/CCM.0b013e3181957532","article-title":"The vasopressin and copeptin response to infection, severe sepsis, and septic shock","volume":"37","author":"Jochberger","year":"2009","journal-title":"Crit Care Med"},{"issue":"3","key":"10.1016\/j.jcrc.2017.03.008_bb0250","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1097\/00003246-200203000-00001","article-title":"Depletion of neurohypophyseal content of vasopressin in septic shock","volume":"30","author":"Sharshar","year":"2002","journal-title":"Crit Care Med"},{"issue":"4","key":"10.1016\/j.jcrc.2017.03.008_bb0255","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1097\/MCC.0b013e3282435e16","article-title":"Endogenous and exogenous vasopressin in shock","volume":"13","author":"Oliver","year":"2007","journal-title":"Curr Opin Crit Care"},{"issue":"9","key":"10.1016\/j.jcrc.2017.03.008_bb0260","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1007\/BF03022837","article-title":"Review article: organ perfusion\/permeability-related effects of norepinephrine and vasopressin in sepsis","volume":"53","author":"Farand","year":"2006","journal-title":"Can J Anaesth"},{"issue":"1","key":"10.1016\/j.jcrc.2017.03.008_bb0265","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1097\/01.CCM.0000251127.45385.CD","article-title":"Vasopressin: mechanisms of action on the vasculature in health and in septic shock","volume":"35","author":"Barrett","year":"2007","journal-title":"Crit Care Med"},{"issue":"9 Suppl","key":"10.1016\/j.jcrc.2017.03.008_bb0270","doi-asserted-by":"crossref","first-page":"S609","DOI":"10.1097\/01.CCM.0000279158.51481.41","article-title":"Vasopressin in septic shock","volume":"35","author":"Russell","year":"2007","journal-title":"Crit Care Med"},{"issue":"4","key":"10.1016\/j.jcrc.2017.03.008_bb0275","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1097\/MCC.0b013e328263885e","article-title":"Vasopressin in vasodilatory and septic shock","volume":"13","author":"Russell","year":"2007","journal-title":"Curr Opin Crit Care"},{"issue":"1","key":"10.1016\/j.jcrc.2017.03.008_bb0280","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s00134-009-1687-x","article-title":"The effects of vasopressin on acute kidney injury in septic shock","volume":"36","author":"Gordon","year":"2010","journal-title":"Intensive Care Med"},{"issue":"3","key":"10.1016\/j.jcrc.2017.03.008_bb0285","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1097\/CCM.0b013e3181961ace","article-title":"Interaction of vasopressin infusion, corticosteroid treatment, and mortality of septic shock","volume":"37","author":"Russell","year":"2009","journal-title":"Crit Care Med"},{"issue":"3","key":"10.1016\/j.jcrc.2017.03.008_bb0290","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1097\/01.shk.0000235140.97903.90","article-title":"Methylprednisolone reverses vasopressin hyporesponsiveness in ovine endotoxemia","volume":"27","author":"Ertmer","year":"2007","journal-title":"Shock"},{"issue":"3","key":"10.1016\/j.jcrc.2017.03.008_bb0295","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1097\/CCM.0b013e31819879c1","article-title":"Vasopressin plus corticosteroids: the shock duo!","volume":"37","author":"Annane","year":"2009","journal-title":"Crit Care Med"},{"issue":"5","key":"10.1016\/j.jcrc.2017.03.008_bb0300","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1001\/jama.2016.10485","article-title":"Effect of early vasopressin vs norepinephrine on kidney failure in patients with septic shock: The VANISH randomized clinical trial","volume":"316","author":"Gordon","year":"2016","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.jcrc.2017.03.008_bb0305","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0168-8278(98)80184-0","article-title":"Hemodynamic effects of terlipressin and octreotide administration alone or in combination in portal hypertensive rats","volume":"29","author":"Oberti","year":"1998","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.jcrc.2017.03.008_bb0310","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1002\/hep.510270206","article-title":"Effects of F-180, a new selective vasoconstrictor peptide, compared with terlipressin and vasopressin on systemic and splanchnic hemodynamics in a rat model of portal hypertension","volume":"27","author":"Bernadich","year":"1998","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.jcrc.2017.03.008_bb0315","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1097\/01.CCM.0000152253.45901.FB","article-title":"Low-dose terlipressin during long-term hyperdynamic porcine endotoxemia: effects on hepatosplanchnic perfusion, oxygen exchange, and metabolism","volume":"33","author":"Asfar","year":"2005","journal-title":"Crit Care Med"},{"issue":"4","key":"10.1016\/j.jcrc.2017.03.008_bb0320","doi-asserted-by":"crossref","first-page":"R130","DOI":"10.1186\/cc7990","article-title":"Continuous terlipressin versus vasopressin infusion in septic shock (TERLIVAP): a randomized, controlled pilot study","volume":"13","author":"Morelli","year":"2009","journal-title":"Crit Care"},{"issue":"18","key":"10.1016\/j.jcrc.2017.03.008_bb0325","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1056\/NEJMra1208943","article-title":"Circulatory shock","volume":"369","author":"Vincent","year":"2013","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.jcrc.2017.03.008_bb0330","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1124\/jpet.111.178848","article-title":"Pharmacological characterization of FE 202158, a novel, potent, selective, and short-acting peptidic vasopressin V1a receptor full agonist for the treatment of vasodilatory hypotension","volume":"337","author":"Laporte","year":"2011","journal-title":"J Pharmacol Exp Ther"},{"issue":"13","key":"10.1016\/j.jcrc.2017.03.008_bb0335","doi-asserted-by":"crossref","first-page":"4388","DOI":"10.1021\/jm200278m","article-title":"New, potent, selective, and short-acting peptidic V1a receptor agonists","volume":"54","author":"Wisniewski","year":"2011","journal-title":"J Med Chem"},{"issue":"12","key":"10.1016\/j.jcrc.2017.03.008_bb0340","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1007\/s00134-015-3849-3","article-title":"What's new in vasopressin?","volume":"41","author":"O'Callaghan","year":"2015","journal-title":"Intensive Care Med"},{"issue":"6","key":"10.1016\/j.jcrc.2017.03.008_bb0345","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1097\/CCM.0b013e31824e0fe5","article-title":"Unlike arginine vasopressin, the selective V1a receptor agonist FE 202158 does not cause procoagulant effects by releasing von Willebrand factor","volume":"40","author":"Rehberg","year":"2012","journal-title":"Crit Care Med"},{"issue":"7","key":"10.1016\/j.jcrc.2017.03.008_bb0350","doi-asserted-by":"crossref","first-page":"e525","DOI":"10.1097\/CCM.0000000000000300","article-title":"The selective vasopressin type 1a receptor agonist selepressin (FE 202158) blocks vascular leak in ovine severe sepsis*","volume":"42","author":"Maybauer","year":"2014","journal-title":"Crit Care Med"},{"issue":"1","key":"10.1016\/j.jcrc.2017.03.008_bb0355","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1097\/CCM.0000000000001380","article-title":"A selective V(1A) receptor agonist, selepressin, is superior to arginine vasopressin and to norepinephrine in ovine septic shock","volume":"44","author":"He","year":"2016","journal-title":"Crit Care Med"},{"issue":"2","key":"10.1016\/j.jcrc.2017.03.008_bb0360","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1097\/01.CCM.0000194725.48928.3A","article-title":"Sepsis in European intensive care units: results of the SOAP study","volume":"34","author":"Vincent","year":"2006","journal-title":"Crit Care Med"},{"issue":"2","key":"10.1016\/j.jcrc.2017.03.008_bb0365","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1097\/CCM.0b013e3181feeb15","article-title":"Fluid resuscitation in septic shock: A positive fluid balance and elevated central venous pressure are associated with increased mortality","volume":"39","author":"Boyd","year":"2011","journal-title":"Crit Care Med"},{"issue":"10","key":"10.1016\/j.jcrc.2017.03.008_bb0370","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0165422","article-title":"Selepressin and arginine vasopressin do not display cardiovascular risk in atherosclerotic rabbit","volume":"11","author":"Boucheix","year":"2016","journal-title":"PLoS One"},{"issue":"12 Suppl 1","key":"10.1016\/j.jcrc.2017.03.008_bb0375","first-page":"1","volume":"40","year":"2012","journal-title":"Crit Care Med"},{"issue":"9","key":"10.1016\/j.jcrc.2017.03.008_bb0380","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1001\/jama.2014.18484","article-title":"Critical care evidence\u2014new directions","volume":"313","author":"Marini","year":"2015","journal-title":"JAMA"}],"container-title":["Journal of Critical Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0883944116307948?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0883944116307948?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,3]],"date-time":"2018-09-03T14:55:30Z","timestamp":1535986530000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0883944116307948"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8]]},"references-count":76,"alternative-id":["S0883944116307948"],"URL":"https:\/\/doi.org\/10.1016\/j.jcrc.2017.03.008","relation":{},"ISSN":["0883-9441"],"issn-type":[{"value":"0883-9441","type":"print"}],"subject":[],"published":{"date-parts":[[2017,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The role of vasopressin and the vasopressin type V1a receptor agonist selepressin in septic shock","name":"articletitle","label":"Article Title"},{"value":"Journal of Critical Care","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcrc.2017.03.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}